Novavax, Inc. (NASDAQ: NVAX)
Novavax is having an incredible day in the market today after announcing top-line data from their most recent Phase 2 clinical trial. Today, we’ll take a look at the data, how the market reacted, and what we can expect from NVAX moving forward. So, let’s get right to it…
Novavax Phase 2 Trial Data
As mentioned above, Novavax announced the results of its most recent Phase 2 clinical trial this morning. The trial looked into the company’s RSV F-protein recombinant nanopartile vaccine candidate and its effectiveness in adults age 60 or older. The top-line data showed that the RSV F Vaccine was well-tolerated and ultimately fulfilled both the company’s primary and secondary objectives associated with the trial. Upon the release of the data, Dr. William Schaffner, Professor of Preventative Medicine and Infectious Diseases at Vanderbilt University Medical Center had the following to say…
“It’s increasingly appreciated that RSV causes an enormous amount of illness on an annual basis, particularly in the older population. An RSV infection can predispose older adults to developing secondary pneumonia and admission to the hospital… Each year in the United States, approximately 14,000 people ages 65 or older die of RSV infections and approximately 900,000 have some sort of medical encounter with a doctor, or emergency room, or are hospitalized. Prevention remains the highest goal of medicine and those of us in preventative medicine and public health would like to prevent as many of these infections as possible.”
How The Market Reacted To The News
As we’ve come to expect any time we see positive top-line data from clinical trials, NVAX is having an incredible day in the market. Currently (12:45), the stock is trading at $13.81 per share after a gain of 23.46% as investors continue to show their excitement that revolves around the new data.
What We Can Expect To See Moving Forward
Moving forward, I’m expecting to see overwhelmingly positive news from NVAX. While we may see a slight dip from today’s highs before upward momentum continues, in my opinion, the stock is destined for growth. The reality is that the company’s RSV F vaccine is proving to be well-tolerated and effective in patients age 60 or older. Now, it’s time to move on to Phase 3; which I believe will eventually lead to FDA approval and massive growth for the company. So, keep your eyes locked on NVAX as it’s likely to present several strong opportunities for profit.
What Do You Think?
Where do you think NVAX is headed and why? Let us know in the comments below!